Skip to main content
. 2020 Sep 22;20(4):319–330. doi: 10.1007/s40268-020-00320-5
Monoclonal antibody (mAb)-induced subacute cutaneous lupus erythematosus (SCLE) has been reported in 52 patients across a range of 17 mAbs.
Adalimumab, denosumab and rituximab were estimated to have the greatest number of annual users.
Checkpoint inhibitors and anti-tumour necrosis factor-ɑ agents are associated with high rates of SCLE relative to the estimated global yearly use and other mAbs.